The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•7 May 2026•

1 min read

Photocure ASA Reports Strong Q1 2026 Growth and Positive Full-Year Revenue Guidance

Key Facts

1Photocure reported Hexvix/Cysview revenues of NOK 139.0 million in the first quarter of 2026.

2Adjusted EBITDA rose to NOK 15.3 million compared to NOK 9.7 million in the previous year.

Photocure ASA reported its financial results for the first quarter of 2026, highlighting Hexvix/Cysview product revenues of NOK 139.0 million. The company's adjusted EBITDA saw a significant increase to NOK 15.3 million, up from NOK 9.7 million in the prior-year period. This robust performance underscores improved operating margins and strong momentum for the company's core product offerings. Looking ahead, Photocure maintains a positive outlook, forecasting product revenue growth between 7% and 11% for the full year 2026 on a constant currency basis. These results reinforce investor confidence in the firm's financial trajectory and its ability to meet annual targets within the healthcare sector. Market participants are closely monitoring the sustainability of this growth amid broader economic conditions.